What is Osphena®?
Osphena® is the only FDA-approved oral pill indicated for the treatment of moderate to severe dyspareunia (painful sex), a symptom of vulvar and vaginal atrophy (VVA), due to menopause.
Just one oral, hormone-free pill daily can relieve moderate to severe painful sex after menopause in as little as 12 weeks*.
Osphena® is not an estrogen, but it works like one to help improve the condition of specific vaginal tissue** and help relieve moderate to severe painful sex due to menopause.
*You and your healthcare provider should talk regularly (every 3 to 6 months) about the dose you are taking and whether or not you still need treatment with Osphena®.
**Increases superficial cells, decreases parabasal cells (two types of vaginal cells) and reduces vaginal pH.
What is the most important safety information I should know about Osphena®?
- Osphena® is a medicine that works like estrogen in the lining of the uterus (womb), but can work differently in other parts of the body. Taking estrogen-alone or Osphena® may increase your chance of getting cancer of the lining of the uterus (womb). Vaginal bleeding after menopause may be a warning sign of cancer of the lining of the uterus (womb). Your healthcare provider should check any unusual vaginal bleeding to find out the cause. Tell your healthcare provider right away if you have any unusual vaginal bleeding while you are taking Osphena®.
- Osphena® may increase your chance of having a stroke or blood clots.
- You and your healthcare provider should talk regularly about whether you still need treatment with Osphena®.
Call your healthcare provider right away if you get any of the following warning signs or any other unusual symptoms that concern you:
- unusual vaginal bleeding
- changes in vision or speech
- sudden new severe headaches
- severe pains in your chest or legs with or without shortness of breath, weakness and fatigue
1 ACOG Practice Bullet Number 141: Management of menopausal symptoms. Practice Bulletin No. 141. American College of Obstetricians and Gynecologists. Obstet Gynecol. 2014:123(1):202-216.
2 North American Menopause Society. Management of symptomatic vulvovaginal atrophy: 2013 position statement of the North American Menopause Society. Menopause. 2013;20(9):888-902.